MA56129A - Procédés de production d'un anticorps anti-alpha4béta7 - Google Patents

Procédés de production d'un anticorps anti-alpha4béta7

Info

Publication number
MA56129A
MA56129A MA056129A MA56129A MA56129A MA 56129 A MA56129 A MA 56129A MA 056129 A MA056129 A MA 056129A MA 56129 A MA56129 A MA 56129A MA 56129 A MA56129 A MA 56129A
Authority
MA
Morocco
Prior art keywords
antibody
producing
methods
Prior art date
Application number
MA056129A
Other languages
English (en)
Inventor
Debra Ameli
Paras Bhatia
Susan R Carter
Michael E Dolan
Nicole Hilo
Amitava Kundu
Amy Miller
Olga Paley
George Parks
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA56129A publication Critical patent/MA56129A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056129A 2019-06-10 2020-06-10 Procédés de production d'un anticorps anti-alpha4béta7 MA56129A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10

Publications (1)

Publication Number Publication Date
MA56129A true MA56129A (fr) 2022-04-13

Family

ID=73781728

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056129A MA56129A (fr) 2019-06-10 2020-06-10 Procédés de production d'un anticorps anti-alpha4béta7

Country Status (14)

Country Link
US (1) US20220267449A1 (fr)
EP (1) EP3980466A4 (fr)
JP (2) JP7624414B2 (fr)
CN (2) CN114375307B (fr)
AR (1) AR119270A1 (fr)
AU (1) AU2020290943A1 (fr)
BR (1) BR112021024897A2 (fr)
CA (1) CA3143167A1 (fr)
IL (1) IL288825A (fr)
MA (1) MA56129A (fr)
MX (1) MX2021015300A (fr)
PL (1) PL439809A1 (fr)
TW (1) TW202112818A (fr)
WO (1) WO2020252069A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198099A1 (fr) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Formulation d'anticorps stable
EP3773696A4 (fr) 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Formulations stables d'anticorps thérapeutique
WO2023007516A1 (fr) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Procédé de régulation d'agrégats de poids moléculaire élevé dans une composition d'anticorps
WO2023012828A1 (fr) * 2021-08-05 2023-02-09 Dr. Reddy's Laboratories Limited Procédé de purification d'une composition d'anticorps au moyen d'une chromatographie par échange de cations
WO2023031965A1 (fr) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Procédé d'obtention d'une composition d'anticorps purifiée
WO2024233992A2 (fr) * 2023-05-11 2024-11-14 Trophogen, Inc. Procédés de fabrication d'hormones de glycoprotéine hautement glycosylées et leurs analogues
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (fr) * 2013-03-14 2014-09-18 Abbvie Inc. Purification de protéine utilisant une chromatographie de déplacement
JP6293907B2 (ja) * 2014-03-10 2018-03-14 リヒター ゲデオン エヌワイアールティー． プレクリーニング工程を用いた免疫グロブリンの精製
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
IL288825A (en) 2022-02-01
JP7624414B2 (ja) 2025-01-30
CN114375307B (zh) 2025-12-05
JP2025063035A (ja) 2025-04-15
US20220267449A1 (en) 2022-08-25
EP3980466A4 (fr) 2023-06-07
CN119859188A (zh) 2025-04-22
AU2020290943A1 (en) 2022-02-03
WO2020252069A1 (fr) 2020-12-17
MX2021015300A (es) 2022-02-03
BR112021024897A2 (pt) 2022-01-18
PL439809A1 (pl) 2022-12-05
TW202112818A (zh) 2021-04-01
JP2022536486A (ja) 2022-08-17
CN114375307A (zh) 2022-04-19
EP3980466A1 (fr) 2022-04-13
AR119270A1 (es) 2021-12-09
CA3143167A1 (fr) 2020-12-17

Similar Documents

Publication Publication Date Title
MA56129A (fr) Procédés de production d'un anticorps anti-alpha4béta7
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
MA49034B1 (fr) Anticorps anti-lag3
MA55284A (fr) Procédés de production de compositions d'anticorps anti-tnf
EP3752535A4 (fr) Procédé de production d'anticorps monoclonal hu14.18k322a
MA55363A (fr) Anticorps multispécifiques egfr x cd28
EP3907290A4 (fr) Micro-organisme produisant du biorétinol et procédé de production de biorétinol l'utilisant
EP3464348A4 (fr) Procédés de production d'anticorps actifs à partir de fluides biologiques
PL3990411T3 (pl) Sposób wytwarzania reagentów cementowych
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3363818A4 (fr) Procédé de production d'une paire de mutants hétérodimères du domaine ch3 d'anticorps utilisant l'appariement de levures et paire mutante de ch3 ainsi produite
EP4059051A4 (fr) Ensembles intégrés et procédés de formation d'ensembles intégrés
MA51417A (fr) Constructions d'anticorps bispécifiques dirigés contre muc17 et cd3
EP3836359A4 (fr) Induit et procédé de production d'induit
MA55283A (fr) Procédés de production de compositions d'anticorps anti-tnf
MA54090A (fr) Production enzymatique d'hexoses
EP4028032A4 (fr) Immunothérapie cellulaire car d'anticorps bispécifique
EP3972627A4 (fr) Procédés de préparation de conjugués psma
IL286306A (en) Manufacturing methods for producing anti-tnf antibody compositions
EP3452084A4 (fr) Anticorps anti-kv 1.3 et procédés pour les produire et les utiliser
EP3947409A4 (fr) Production biosynthétique d'udp-rhamnose
PL4043451T3 (pl) Sposoby wytwarzania związku pośredniego w syntezie kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2h-pirazolo-3-karboksylowego
MA52217A (fr) Variants d'anticorps anti-c-terminal
EP3867354A4 (fr) Compositions et procédés de production d'organoïdes tumoraux
EP3619531A4 (fr) Biocapteurs produits à partir d'enzymes à solubilité réduite et leurs procédés de production et d'utilisation